Related Experiment Video

Updated: Mar 25, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Ajay Bhargava1, Steven Pelech2, Ben Woodard3

  • 1Shakti BioResearch, Woodbridge, United States.

Elife
|February 17, 2016
PubMed

Insights

This study replicates key experiments on RAF inhibitors in cancer biology, investigating their paradoxical effects on tumor cell viability and MAPK pathway activation. Findings aim to enhance reproducibility in cancer research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Reproducibility is a significant concern in scientific research, particularly in cancer biology.
  • High-profile cancer biology papers published between 2010-2012 were selected for replication based on citations and Altmetric scores.
  • The original study by Hatzivassiliou et al. (2010) explored the paradoxical activation of the MAPK pathway by RAF inhibitors in wild-type RAF tumors.

Purpose of the Study:

  • To conduct a registered replication of key experiments from Hatzivassiliou et al. (2010) published in Nature.
  • To verify the findings regarding RAF inhibitor effects on cell viability, MAPK pathway activation, and protein dimerization.
  • To contribute to the Reproducibility Project: Cancer Biology's goal of assessing the reliability of cancer research findings.

Main Methods:

  • Replication of experiments from Hatzivassiliou et al. (2010), focusing on Figures 1A, 2B, and 4A.
  • Investigating the effect of RAF small molecule inhibitors on BRAF(WT) tumor cell line viability.
  • Assessing the dependency of RAF inhibitor-induced MAPK pathway activation on CRAF and BRAF.
  • Examining the modulation of BRAF and CRAF dimerization by specific RAF inhibitors (PLX4720 and GDC-0879).

Main Results:

  • The replication plan details the methodology for verifying the original study's findings.
  • Specific focus on the paradoxical increase in cell viability observed with RAF inhibitors in certain tumor cell lines.
  • Detailed examination of the role of CRAF versus BRAF in RAF inhibitor-mediated MAPK pathway activation.
  • Analysis of RAF inhibitor effects on BRAF-CRAF dimerization.

Conclusions:

  • The results of this replication study will be published by eLife.
  • This work aims to provide transparent and reproducible data to the cancer research community.
  • The findings will help clarify the complex interactions between RAF inhibitors, the MAPK pathway, and tumor growth.
Keywords:
BRAF inhibitorshumanhuman biologymedicinemethodologyparadoxical activationreproducibility project: cancer biology

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

905

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K